⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
ABBV — AbbVie Inc.
Last scan (Oct. 5, 2026): price $262.82, RSI 53.78, relative volume 1.42x, MACD ⚪ No, score 18.45.
It's in a bullish underlying trend (above its 200-day average), with an RSI of 53.78 in a neutral zone. Neither the MACD nor a range breakout gives a technical entry signal right now. Relative volume of 1.42x is somewhat above normal. The analysts' average target price implies a modest +6.1% upside. With a PEG of 0.54, the price looks cheap relative to how fast earnings are expected to grow. Today it holds rank #19 in the Monsters group on Smart Scanner's upside + relative volume ranking.
Price chart
ABBV
Price: $262.82 · RSI (14): 72.58 · Rel. volume: 0.12x · Breakout: Yes
- Current price: ($262.82) — solid white line — the latest available closing price.
- Target price: ($278.86) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($241.2) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
ABBV
AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients…
- Buy 24
- Hold 5
- Sell 1
Average target price: $278.86 (+6.1% vs. current price) · range $200.0 – $328.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
?
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
High: the market is paying a premium, usually because it expects strong growth. If the company doesn't deliver, the price could correct sharply.
?
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
?
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Below 1: the price could be cheap relative to how much its earnings are expected to grow.
?
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Not enough data.
?
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Healthy margin for most industries.
?
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Pays out a portion of its earnings as cash to shareholders on a recurring basis.
?
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Less volatile than the overall market (S&P 500 = 1.0).
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.